210 related articles for article (PubMed ID: 22611755)
1. Expression of MUC1 (Ma695) in noninvasive papillary urothelial neoplasm according to the 2004 World Health Organization classification of the noninvasive urothelial neoplasm. An immunologic tool for the pathologist?
Garbar C; Mascaux C
Anal Quant Cytol Histol; 2011 Oct; 33(5):277-82. PubMed ID: 22611755
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of MUC1 and P53 expressions in noninvasive papillary urothelial neoplasms of bladder, their relationship with tumor grade and role in the differential diagnosis.
Kaymaz E; Ozer E; Unverdi H; Hucumenoglu S
Indian J Pathol Microbiol; 2017; 60(4):510-514. PubMed ID: 29323063
[TBL] [Abstract][Full Text] [Related]
3. Cytologic diagnosis of low-grade papillary urothelial neoplasms (low malignant potential and low-grade carcinoma) in the context of the 1998 WHO/ISUP classification.
Whisnant RE; Bastacky SI; Ohori NP
Diagn Cytopathol; 2003 Apr; 28(4):186-90. PubMed ID: 12672093
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression profiles of MUC1 and MUC2 mucins in urothelial tumors of bladder.
Gonul II; Cakir A; Sozen S
Indian J Pathol Microbiol; 2018; 61(3):350-355. PubMed ID: 30004053
[TBL] [Abstract][Full Text] [Related]
5. Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered grading system) on reproducibility.
Tuna B; Yörükoglu K; Düzcan E; Sen S; Nese N; Sarsık B; Akder A; Sayhan S; Mungan U; Kirkali Z
Virchows Arch; 2011 Jun; 458(6):659-64. PubMed ID: 21484429
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth.
Maxwell JP; Wang C; Wiebe N; Yilmaz A; Trpkov K
Diagn Pathol; 2015 Mar; 10():3. PubMed ID: 25886613
[TBL] [Abstract][Full Text] [Related]
7. Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) After Initial TUR-BT: Comparative Analyses with Noninvasive Low-Grade Papillary Urothelial Carcinoma (LGPUC).
Kim JK; Moon KC; Jeong CW; Kwak C; Kim HH; Ku JH
J Cancer; 2017; 8(15):2885-2891. PubMed ID: 28928878
[No Abstract] [Full Text] [Related]
8. Urothelial neoplasms in patients 20 years or younger: a clinicopathological analysis using the world health organization 2004 bladder consensus classification.
Fine SW; Humphrey PA; Dehner LP; Amin MB; Epstein JI
J Urol; 2005 Nov; 174(5):1976-80. PubMed ID: 16217372
[TBL] [Abstract][Full Text] [Related]
9. Histologic grading of urothelial carcinoma: a reappraisal.
Cheng L; MacLennan GT; Lopez-Beltran A
Hum Pathol; 2012 Dec; 43(12):2097-108. PubMed ID: 22542126
[TBL] [Abstract][Full Text] [Related]
10. Utility of ProEx C in the histologic evaluation of the neoplastic and nonneoplastic urothelial lesions.
Moatamed NA; Vergara-Lluri ME; Lu D; Apple SK; Kerkoutian S; Rao JY
Hum Pathol; 2013 Nov; 44(11):2509-17. PubMed ID: 24029711
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
[TBL] [Abstract][Full Text] [Related]
12. P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification.
Kalantari MR; Ahmadnia H
Urol J; 2007; 4(4):230-3. PubMed ID: 18270948
[TBL] [Abstract][Full Text] [Related]
13. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.
Barbisan F; Santinelli A; Mazzucchelli R; Lopez-Beltran A; Cheng L; Scarpelli M; van der Kwast T; Montironi R
Cancer; 2008 Feb; 112(3):636-44. PubMed ID: 18072261
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of p63, p53 in urinary bladder carcinoma.
Koyuncuer A
Indian J Pathol Microbiol; 2013; 56(1):10-5. PubMed ID: 23924551
[TBL] [Abstract][Full Text] [Related]
15. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up.
Yin H; Leong AS
Am J Clin Pathol; 2004 May; 121(5):679-87. PubMed ID: 15151208
[TBL] [Abstract][Full Text] [Related]
16. The 1973 WHO Classification is more suitable than the 2004 WHO Classification for predicting prognosis in non-muscle-invasive bladder cancer.
Chen Z; Ding W; Xu K; Tan J; Sun C; Gou Y; Tong S; Xia G; Fang Z; Ding Q
PLoS One; 2012; 7(10):e47199. PubMed ID: 23082147
[TBL] [Abstract][Full Text] [Related]
17. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder.
Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Navone R
Am J Surg Pathol; 2001 Dec; 25(12):1528-33. PubMed ID: 11717543
[TBL] [Abstract][Full Text] [Related]
18. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy.
Holmäng S; Andius P; Hedelin H; Wester K; Busch C; Johansson SL
J Urol; 2001 Apr; 165(4):1124-8; discussion 1128-30. PubMed ID: 11257652
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system.
Miyamoto H; Miller JS; Fajardo DA; Lee TK; Netto GJ; Epstein JI
Pathol Int; 2010 Jan; 60(1):1-8. PubMed ID: 20055945
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study on expression and clinical significance of PHH3, Ki67 and P53 in bladder exophytic papillary urothelial neoplasms.
Qi G; Liu J; Tao S; Fan W; Zheng H; Wang M; Yang H; Liu Y; Liu H; Zhou F
PeerJ; 2023; 11():e15675. PubMed ID: 37456895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
